Service Overview
End-to-End Value Proposition
CLB CDMO Services
CLB strives to provide global clients with clinical development and commercial supply of biosimilars and innovative biologics.
- End-to-end value proposition ranging from DNA to IND to commercial manufacturing;
- State-of-the-art facility with scientific expertise to deliver high-quality, cost-effective and fast-to-market products;
- Highly experienced international team;
- Flexible business models;
- Global regulatory support.
(click image to see details)